Citations

Bacterial Toxin Research Citations

We’ve gathered published citations for the past many years so that researchers can easily review at their convenience from among the thousands of published articles, how they might use our products in detail or apply these ideas to their own novel thinking for new research.

Search through, read and share our information rich citations below!

Contact us with any questions.

5027 total record number 57 records this year

To narrow your search, use one or more of the following search menus below.

To search by keyword, you may search by the cell/animal/assay/protein/research or publication
Page 2 out of 35
344 citations found

Immunogenicity and efficacy studies of Endo H in vivo deglycosylated Protective Antigen from Bacillus anthracis as a vaccine candidate against anthrax

Mamedov, T;Gun, N;Gulec, B;Khozeini, H;Ungor, R;Yuksel, D;Arslan, A;Dilik, Z;Deniz, D;Goven, N;Mammadova, G;Hasanova, G;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

  • Immunogenicity Studies of PA83 variants in Mice

    Immunogenicity studies were performed with 3 and 10 μg of plant-produced dPA83(E), dPA83(P) and commercial recombinant PA (rPA, List Biological Laboratories, Campbell, CA, used as a positive control) proteins, administered intraperitoneally in seven- to eight-week-old Balb/c mice (6 animals/group). Mice were injected with three doses of protein samples adsorbed in 0.3% Alhydrogel at three-week intervals (day 0, 21 and 42). …

    Product #171E – Anthrax Protective Antigen (PA), Recombinant from B. anthracis

Species-specific NLRP3 regulation and its role in CNS autoinflammatory diseases

Koller, B;Nguyen, M;Snouwaert, J;Gabel, C;Ting, J;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

  • Anthrax lethal toxin List Biological Laboratories Inc. #171B/#172B

    Treatments

    See Table S1 for list of Figures/panels in each figure and corresponding dose and exposure time. General information for the methods is provided here. To induce cytokine release from macrophages, microglia and BMDM cells were primed for 4–5 h (or time indicated in Table S1)with 1 μg/mL of LPS in culture medium, and some cells were pre-treated with 1 μM of CP456773/MCC950 for 30 min before ATP stimulation. Cells were then pulsed with 5 mM ATP for 30 min. For cytokine induction by anthrax lethal toxin (LeTx), LPS-primed cells were treated with LeTx at a final concentration of 250 ng/mL (LF and PA) for 3 h. Cell supernatants were collected and frozen at −80°C until assayed.

    Product #171E – Anthrax Protective Antigen (PA), Recombinant from B. anthracis
    Prodcut #172 – Anthrax Lethal Factor (LF), Recombinant from B. anthracis

Early Circulating Edema Factor in Inhalational Anthrax Infection: Does It Matter?

Tessier, E;Cheutin, L;Garnier, A;Vigne, C;Tournier, JN;Rougeaux, C;

Product: Anti-Edema Factor from B. anthracis (Goat)

  • goat anti-EF (773L, List Labs, Campbell, CA, USA), …

Product: Anthrax Lethal Factor (LF), Recombinant from B. anthracis

Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders

Harrison, D;Billinton, A;Bock, MG;Doedens, JR;Gabel, CA;Holloway, MK;Porter, RA;Reader, V;Scanlon, J;Schooley, K;Watt, AP;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

Anthrax lethal toxin and tumor necrosis factor-α synergize on intestinal epithelia to induce mouse death

Gao, X;Teng, T;Liu, Y;Ai, T;Zhao, R;Fu, Y;Zhang, P;Han, J;Zhang, Y;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

Muscimol inhibits plasma membrane rupture and ninjurin-1 oligomerization during pyroptosis

den Hartigh, AB;Loomis, WP;Anderson, MJ;Frølund, B;Fink, SL;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

Ros-Dependent Palmitoylation Activates Pore Formation by Cleaved and Intact Gsdmd

Du, G;Healy, L;David, L;Walker, C;El-Baba, T;Lutomski, C;Goh, B;Pi, X;Fontana, P;Dong, Y;Ma, X;Miao, R;Devant, P;Puthenveetil, R;Banerjee, A;Kagan, J;Oh, S;Robinson, C;Lieberman, J;Wu, H;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

Inhalable vaccine of bacterial culture supernatant extract mediates protection against fatal pulmonary anthrax

Zhai, LN;Zhao, Y;Song, XL;Qin, TT;Zhang, ZJ;Wang, JZ;Sui, CY;Zhang, LL;Lv, M;Hu, LF;Zhou, DS;Fang, TY;Yang, WH;Wang, YC;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

  • Culture supernatant extract anthrax vaccine and its liquid and dry powder formulations preparation and characterization

    … Total protein concentrations of the CSE vaccine were measured by bicinchoninic acid assay (BCA, Gene-Star, Beijing, China). An enzyme-linked immunosorbent assay (ELISA, Dakewe, Beijing, China) was used to quantify the PA protein in the CSE vaccine according to a previously method [Citation20]. Serially diluted commercial recombinant PA (rPA, 171E, List Labs, Campbell, CA, USA) was the reference standard. …

    Product #171E – Anthrax Protective Antigen (PA), Recombinant from B. anthracis